WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuParasitic infections
Ouvrir ce répertoire et afficher son contenuInsect and arachnid bites and stings
Ouvrir ce répertoire et afficher son contenuSuperficial fungal infections
Ouvrir ce répertoire et afficher son contenuSubcutaneous fungal infections
Ouvrir ce répertoire et afficher son contenuBacterial infections
Ouvrir ce répertoire et afficher son contenuViral infections
Ouvrir ce répertoire et afficher son contenuEczematous diseases
Ouvrir ce répertoire et afficher son contenuScaling diseases
Ouvrir ce répertoire et afficher son contenuPapulosquamous diseases
Afficher le documentCutaneous reactions to drugs
Ouvrir ce répertoire et afficher son contenuPigmentary disorders
Ouvrir ce répertoire et afficher son contenuPremalignant lesions and malignant tumours
Ouvrir ce répertoire et afficher son contenuPhotodermatoses
Ouvrir ce répertoire et afficher son contenuBullous dermatoses
Afficher le documentAlopecia areata
Afficher le documentUrticaria
Fermer ce répertoireConditions common in children
Afficher le documentDiaper dermatitis
Afficher le documentHaemangiomas
Afficher le documentMiliaria
Afficher le documentPityriasis alba (patchy hypochromia)
Afficher le documentAcne vulgaris
Afficher le documentPruritus
Afficher le documentTropical ulcers
Ouvrir ce répertoire et afficher son contenuAntimicrobial drugs
Ouvrir ce répertoire et afficher son contenuAntifugal drugs
Ouvrir ce répertoire et afficher son contenuAntiseptic agents
Ouvrir ce répertoire et afficher son contenuKeratoplastic and keratolytic agents
Ouvrir ce répertoire et afficher son contenuScabicides and pediculicides
Ouvrir ce répertoire et afficher son contenuAnti-inflammatory and antipruritic drugs1
Ouvrir ce répertoire et afficher son contenuAntiallergics and drugs used in anaphylaxis
Ouvrir ce répertoire et afficher son contenuUltraviolet radiation-blocking agents (sunscreens)
Ouvrir ce répertoire et afficher son contenuMiscellaneous drugs
Ouvrir ce répertoire et afficher son contenuAnnex
Afficher le documentSelected WHO Publications of Related Interest
Afficher le documentBack cover
 

Pityriasis alba (patchy hypochromia)

Pityriasis alba (patchy hypochromia) affects over 80% of children living in rural areas of developing countries. The disease is characterized by oval or round, scaly, hypochromic lesions in light-exposed areas. Its etiology is obscure. In developed countries, pityriasis alba, which generally is seen with slight scaling, is often a manifestation of atopy (inflammation causes residual hypopigmentation, which is aggravated by the use of topical corticosteroids). In developing countries, skin dryness, nasal discharge and poor hygiene may favour subclinical bacterial proliferation and parakeratosis. These in turn are clinically manifested as fine desquamation and hypochromia.

Management

While hypochromia is only a minor cosmetic problem, it is often perceived as a health priority. Management should be addressed first to explaining the nature of the disease and its lack of relation to other common conditions in developing countries such as vitamin deficiencies, intestinal parasite infections or other infections. It is also necessary to point out that the disease itself is not contagious. Emollients can be prescribed. In developing countries, a topical preparation consisting of 60% petroleum jelly and 40% zinc oxide with 2% clioquinol powder and 0.5% coal tar is used for this condition. The preparation should be applied at night and washed off in the morning. Treatment usually has to be maintained for 4-6 weeks.

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012